Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Fulcrum Therapeutics Q3 2026 Results: Net Loss of $10.9M, Loss Narrows

Fulcrum Therapeutics is currently pursuing a merger with Slate Medicines, Inc. while undergoing significant restructuring, including the cessation of clinical development for pociredir and a workforce reduction. The company reported a net loss of $56.0 million for the nine months ended September 30, 2026, and currently has no product candidates in active clinical development.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-10.9-19.6
EPS (diluted, $ a share)$-0.14$-0.31

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: FULC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Fulcrum Therapeutics, Inc.: key numbers

Share price
$3.71Close, Nov 16
Market cap
$283M
Shares outstanding
76.38MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Fulcrum Therapeutics, Inc.

All →
4:11 PM ET 8-K
M&A Deal

Fulcrum Therapeutics Signs $7M M&A Deal with Slate Medicines, Inc.

Fulcrum Therapeutics entered into an agreement to sell its early-stage fetal hemoglobin (HbF) assets to an unaffiliated third-party pharmaceutical company for $7.0 million in cash. The sale is a strategic update to its pending merger with Slate Medicines, as the proceeds will be credited to Fulcrum's net cash and are expected to increase the cash dividend declared in connection with the merger.

Value
$7M
Counterparty
Slate Medicines, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.